Raymond James & Associates Collegium Pharmaceutical, Inc Call Options Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding COLL
# of Institutions
236Shares Held
39.4MCall Options Held
84.2KPut Options Held
18.6K-
Black Rock Inc. New York, NY5.79MShares$222 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.41MShares$130 Million0.28% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.63MShares$101 Million1.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.37MShares$90.7 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY2.33MShares$89.3 Million2.23% of portfolio
About COLLEGIUM PHARMACEUTICAL, INC
- Ticker COLL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 34,126,200
- Market Cap $1.31B
- Description
- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...